Everest Medicines and Kezar Life Sciences Receive IND Approval from China NMPA for PALIZADE Trial in Lupus Nephritis (PRNewswire) - Feb 26, 2024 - "Everest Medicines...and Kezar Life Sciences, Inc...announced today that the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) approved Kezar's investigational new drug (IND) application for initiation of the Phase 2b PALIZADE trial in China of zetomipzomib in patients with lupus nephritis (LN)."
Non-US regulatory • Trial status • Lupus Nephritis
|